Genmab A/S

"Antibody-based products for cancer and other diseases" [1]

Where it wins

• DARZALEX royalty rights: Genmab holds co-commercialization rights to daratumumab (DARZALEX), a blockbuster multiple myeloma drug, generating $4.207B in Q2 2026 net sales alone [1].
• DuoBody® platform: Proprietary bispecific antibody technology (e.g., Epcoritamab) that engages T-cells to target CD20+ B-cell malignancies [1].
• Late-stage pipeline: Multiple Phase 3 readouts and launches expected in 2027, including Epcoritamab for first-line DLBCL/FL [1].
• Strong clinical data: Tivdak approved for recurrent/metastatic cervical cancer; EPKINLY/TEPKINLY for R/R DLBCL and FL [1].

Credibility: Q2 2026 earnings report and press releases confirm revenue guidance and clinical trial outcomes [1].

• Biotechnology R&D: Develops antibody-based products through proprietary DuoBody® platform [1].
• Co-commercialization: Partners with Janssen (Johnson & Johnson) for DARZALEX, sharing royalties [1].
• Late-stage pipeline: Advances multiple candidates to Phase 3, with launches expected in 2027 [1].
• Revenue diversification: Balances DARZALEX royalties with growing product sales from EPKINLY, Tivdak, and pipeline candidates [1].
• Public company structure: Listed on NASDAQ (GMAB), with market cap of $18.45B and revenue of $4.13B (TTM) [1].

Credibility: Q2 2026 earnings report, press releases, and stock analysis data [1].

• Janssen (Johnson & Johnson): Co-commercializes DARZALEX, but Genmab holds royalty rights [1].
• Novartis: Competes in multiple myeloma with CAR-T therapies [1].
• Gilead: Competes in lymphoma with CAR-T and bispecifics [1].
• Merck: Competes in cervical cancer with Keytruda [1].
• BMS: Competes in multiple myeloma with Darzalex alternatives [1].

Differentiators: Genmab's DuoBody® platform and DARZALEX royalty rights provide unique revenue streams and pipeline potential [1].

• Limited treatment options: Relapsed/refractory DLBCL and FL patients lack effective therapies [1].
• Chemotherapy resistance: Cervical cancer patients progress on standard chemotherapy [1].
• Multiple myeloma burden: Patients require long-term, high-cost treatments like DARZALEX [1].
• Clinical trial access: Patients need access to late-stage trials for novel therapies [1].
• Payer cost concerns: High drug prices strain healthcare systems [1].

Credibility: Q2 2026 earnings report and press releases confirm product indications and market needs [1].

Genmab's reliance on DARZALEX royalties creates a stable revenue base but limits upside if Janssen's partnership terms change. The failure of Epcoritamab's Phase 3 trial (EPCORE DLBCL-1) poses a near-term risk to pipeline valuation, though first-line indications remain promising. Diversifying revenue through EPKINLY and Tivdak launches reduces dependency on DARZALEX, supporting long-term growth. The next signal to watch is the 2027 Phase 3 readouts for Epcoritamab and other pipeline candidates, which could validate the DuoBody® platform's potential.

Accelerate commercialization of EPKINLY and Tivdak to reduce DARZALEX dependency and diversify revenue streams. Pursue additional partnerships for pipeline candidates to share R&D costs and expand global reach. Enhance patient support programs to improve adherence and outcomes for high-cost therapies. Invest in real-world evidence generation to strengthen payer negotiations and market access for new indications.